Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 2/20 | 0.39 |
| ▸ | KDR | P35968 | 3/20 | 0.39 |
| ▸ | FLT1 | P17948 | 2/20 | 0.39 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.39 |
| ▸ | EPHB2 | P29323 | 1/20 | 0.39 |
| ▸ | FLT4 | P35916 | 1/20 | 0.39 |
| ▸ | CGAS | Q8N884 | 1/20 | 0.38 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.37 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.37 |
| ▸ | RET | P07949 | 3/20 | 0.36 |
| ▸ | KIF5B | P33176 | 3/20 | 0.36 |
| ▸ | EGFR | P00533 | 2/20 | 0.36 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.35 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL382814 | 0.89 | SRC (0.48) | SRCKDRFLT1PDGFRACGAS | |
| SCHEMBL29612582 | 0.89 | SRC (0.48) | SRCKDRFLT1PDGFRACGAS | |
| SCHEMBL2064039 | 0.83 | SRC (0.48) | SRCKDRFLT1PDGFRACGAS | |
| SCHEMBL23597420 | 0.78 | EGFR (0.47) | SRCKDRPDGFRARETKIF5B | |
| SCHEMBL30498652 | 0.78 | EGFR (0.47) | SRCKDRPDGFRARETKIF5B | |
| SCHEMBL4020394 | 0.78 | ENPP1 (0.51) | KDRFLT1RETKIF5BEGFR | |
| SCHEMBL29576809 | 0.77 | TLR8 (0.43) | TLR8EGFR | |
| SCHEMBL2748326 | 0.77 | TLR8 (0.43) | TLR8EGFR | |
| SCHEMBL10296329 | 0.76 | PDGFRB (0.55) | SRCPDGFRAEGFRPDGFRB | |
| SCHEMBL29576504 | 0.76 | SRC (0.60) | SRCPDGFRACGASEGFRPDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110117084-A1 | VANDETANIB DERIVATIVES | CONCERT PHARMACEUTICALS, INC. (US) | 2011-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110117084-A1 | VANDETANIB DERIVATIVES | KDR, VHL, FLT4 | SRC 203/4885KDR 1/4885FLT1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.